Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Quest Diagnostics Reports First Quarter 2022 Financial Results; Raises Guidance for Full Year 2022

      Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

      News provided by

      Quest Diagnostics

      Apr 21, 2022, 06:45 ET

      Share this article

      Share this article


      • First quarter revenues of $2.61 billion, down 4.0% from 2021
      • First quarter reported diluted earnings per share ("EPS") of $2.92, down 15.6% from 2021; and adjusted diluted EPS of $3.22, down 14.4% from 2021
      • Base business revenues of $2.01 billion, up 6.3% from 2021
      • Full year 2022 reported diluted EPS now expected to be between $7.88 and $8.38; and adjusted diluted EPS expected to be between $9.00 and $9.50

      SECAUCUS, N.J., April 21, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2022.

      "We're off to a good start in 2022, as we drove strong year-over-year growth in our base business, which excludes COVID-19 testing," said Steve Rusckowski, Chairman, CEO and President. "COVID-19 volumes remained strong early in the quarter and decreased in February and March, in line with the market. We continue to make investments to further accelerate growth in the base business, while our efforts to improve productivity are helping us to offset inflationary pressures. Based on our strong performance in the quarter and our expectations for the remainder of 2022 we have raised our full year guidance."    


      Three Months Ended March 31,



      2022


      2021


      Change



      (dollars in millions, except per share data)


      Reported:







      Net revenues

      $     2,611


      $     2,720


      (4.0)%


           Base business revenues (a)

      $     2,012


      $     1,892


      6.3%


           COVID-19 testing revenues

      $        599


      $        828


      (27.6)%









           Diagnostic information services revenues

      $     2,541


      $     2,643


      (3.9)%


                Revenue per requisition





      (5.2)%


                Requisition volume





      1.3%


                Organic requisition volume





      —%


      Operating income (b)

      $         513


      $         660


      (22.3)%


      Operating income as a percentage of net revenues (b)

      19.7%


      24.3%


      (4.6)%


      Net income attributable to Quest Diagnostics (b)

      $         355


      $         469


      (24.3)%


      Diluted EPS (b)

      $        2.92


      $        3.46


      (15.6)%


      Cash provided by operations

      $         480


      $         731


      (34.2)%


      Capital expenditures

      $           63


      $           86


      (26.7)%









      Adjusted (b):







      Operating income

      $         554


      $         708


      (21.8)%


      Operating income as a percentage of net revenues

      21.2%


      26.0%


      (4.8)%


      Net income attributable to Quest Diagnostics

      $         392


      $         508


      (23.0)%


      Diluted EPS

      $        3.22


      $        3.76


      (14.4)%




      (a)

      Excludes COVID-19 testing.

      (b)

      For further details impacting the year-over-year comparisons related to operating income, operating
      income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

      Updated Guidance for Full Year 2022

      The company raises its Full Year 2022 guidance as follows:  


      Updated Guidance


      Prior Guidance


      Low


      High


      Low


      High

      Net revenues

      $9.2 billion


      $9.5 billion


      $9.0 billion


      $9.5 billion

      Net revenues decrease

      (14.7)%


      (11.9)%


      (16.6)%


      (11.9)%

           Base business revenues (a)

      $8.35 billion


      $8.50 billion


      $8.3 billion


      $8.5 billion

                Base business revenues increase

      4.1%


      6.0%


      3.5%


      6.0%

           COVID-19 testing revenues

      $0.85 billion


      $1.00 billion


      $0.7 billion


      $1.0 billion

                COVID-19 testing revenues decrease

      (69.3)%


      (63.9)%


      (74.7)%


      (63.9)%

      Reported diluted EPS

      $7.88


      $8.38


      $7.63


      $8.33

      Adjusted diluted EPS

      $9.00


      $9.50


      $8.65


      $9.35

      Cash provided by operations

      At least $1.6 billion


      At least $1.6 billion

      Capital expenditures

        Approximately $400 million


        Approximately $400 million



      (a)

      Excludes COVID-19 testing

      Note on Non-GAAP Financial Measures

      As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, certain financial impacts resulting from the COVID-19 pandemic, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, costs associated with donations, contributions, and other financial support through Quest for Health Equity (our initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities), gains and losses associated with changes in the carrying value of our strategic investments, and other items.

      Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

      Conference Call Information

      Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today.  The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor.  We suggest participants dial in approximately 10 minutes before the call.

      A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on April 21, 2022 until midnight Eastern Time on May 5, 2022, by phone at 800-583-8095 for domestic callers or 203-369-3815 for international callers.  Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

      About Quest Diagnostics

      Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

      Forward Looking Statements

      The statements in this press release which are not historical facts may be forward-looking statements.  Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

      This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.

      ADDITIONAL TABLES FOLLOW

      Quest Diagnostics Incorporated and Subsidiaries

      Consolidated Statements of Operations

      For the Three Months Ended March 31, 2022 and 2021

      (in millions, except per share data)

      (unaudited)



      Three Months Ended
      March 31,


      2022


      2021

      Net revenues

      $    2,611


      $    2,720





      Operating costs and expenses and other operating income:




      Cost of services

      1,646


      1,626

      Selling, general and administrative

      425


      407

      Amortization of intangible assets

      27


      27

           Total operating costs and expenses, net

      2,098


      2,060





      Operating income

      513


      660





      Other income (expense):




      Interest expense, net

      (37)


      (38)

      Other (expense) income, net

      (24)


      4

           Total non-operating expense, net

      (61)


      (34)





      Income before income taxes and equity in earnings of equity method investees

      452


      626

      Income tax expense

      (110)


      (153)

      Equity in earnings of equity method investees, net of taxes

      31


      17

      Net income

      373


      490

      Less: Net income attributable to noncontrolling interests

      18


      21

      Net income attributable to Quest Diagnostics

      $       355


      $       469





      Earnings per share attributable to Quest Diagnostics' common stockholders:




      Basic

      $      2.97


      $      3.52





      Diluted

      $      2.92


      $      3.46





      Weighted average common shares outstanding:




      Basic

      119


      133





      Diluted

      121


      135







      Quest Diagnostics Incorporated and Subsidiaries

      Consolidated Balance Sheets

      March 31, 2022 and December 31, 2021

      (in millions, except per share data)

      (unaudited)



      March 31,
      2022


      December 31,
      2021

      Assets




      Current assets:




      Cash and cash equivalents

      $                 712


      $                872

      Accounts receivable, net

      1,371


      1,438

      Inventories

      197


      208

      Prepaid expenses and other current assets

      195


      223

           Total current assets

      2,475


      2,741

      Property, plant and equipment, net

      1,668


      1,707

      Operating lease right-of-use assets

      620


      597

      Goodwill

      7,197


      7,095

      Intangible assets, net

      1,172


      1,167

      Investments in equity method investees

      155


      141

      Other assets

      155


      163

      Total assets

      $            13,442


      $           13,611





      Liabilities and Stockholders' Equity




      Current liabilities:




      Accounts payable and accrued expenses

      $              1,544


      $             1,600

      Current portion of long-term debt

      2


      2

      Current portion of long-term operating lease liabilities

      154


      151

           Total current liabilities

      1,700


      1,753

      Long-term debt

      3,985


      4,010

      Long-term operating lease liabilities

      522


      494

      Other liabilities

      742


      792

      Redeemable noncontrolling interest

      78


      79

      Stockholders' equity:




      Quest Diagnostics stockholders' equity:




           Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2022 and
            December 31, 2021; 162 shares issued as of both March 31, 2022 and December 31, 2021

      2


      2

           Additional paid-in capital

      2,226


      2,260

           Retained earnings

      7,926


      7,649

           Accumulated other comprehensive loss

      (16)


      (14)

           Treasury stock, at cost; 45 and 43 shares as of March 31, 2022 and December 31, 2021,
           respectively

      (3,761)


      (3,453)

      Total Quest Diagnostics stockholders' equity

      6,377


      6,444

      Noncontrolling interests

      38


      39

           Total stockholders' equity

      6,415


      6,483

      Total liabilities and stockholders' equity

      $            13,442


      $           13,611



      Quest Diagnostics Incorporated and Subsidiaries

      Consolidated Statements of Cash Flows

      For the Three Months Ended March 31, 2022 and 2021

      (in millions)

      (unaudited)



      Three Months Ended March 31,


      2022


      2021

      Cash flows from operating activities:




      Net income

      $              373


      $              490

      Adjustments to reconcile net income to net cash provided by operating activities:




      Depreciation and amortization

      106


      101

      Provision for credit losses

      —


      2

      Deferred income tax benefit

      (43)


      (17)

      Stock-based compensation expense

      18


      18

      Other, net

      4


      (2)

      Changes in operating assets and liabilities:




           Accounts receivable

      72


      138

           Accounts payable and accrued expenses

      (165)


      (164)

           Income taxes payable

      95


      163

           Other assets and liabilities, net

      20


      2

      Net cash provided by operating activities

      480


      731





      Cash flows from investing activities:




      Business acquisitions, net of cash acquired

      (105)


      —

      Capital expenditures

      (63)


      (86)

      Increase in investments and other assets

      (1)


      (7)

      Net cash used in investing activities

      (169)


      (93)





      Cash flows from financing activities:




      Repayments of debt

      (1)


      (1)

      Purchases of treasury stock

      (373)


      (410)

      Exercise of stock options

      10


      17

      Employee payroll tax withholdings on stock issued under stock-based compensation plans

      (27)


      (21)

      Dividends paid

      (74)


      (75)

      Distributions to noncontrolling interest partners

      (20)


      (29)

      Other financing activities, net

      14


      (47)

      Net cash used in financing activities

      (471)


      (566)





      Net change in cash and cash equivalents and restricted cash

      (160)


      72

      Cash and cash equivalents and restricted cash, beginning of period

      872


      1,158

      Cash and cash equivalents and restricted cash, end of period

      $              712


      $           1,230





      Cash paid during the period for:




      Interest

      $                32


      $                32

      Income taxes

      $                23


      $                  7



      Notes to Financial Tables

      1) The computation of basic and diluted earnings per common share is as follows:



      Three Months Ended March 31,


      2022


      2021


      (in millions, except per share data)

      Amounts attributable to Quest Diagnostics' common stockholders:




      Net income attributable to Quest Diagnostics

      $           355


      $           469

      Less: earnings allocated to participating securities

      1


      1

      Earnings available to Quest Diagnostics' common stockholders - basic and diluted

      $           354


      $           468





      Weighted average common shares outstanding - basic

      119


      133

      Effect of dilutive securities:




           Stock options and performance share units

      2


      2

      Weighted average common shares outstanding - diluted

      121


      135





      Earnings per share attributable to Quest Diagnostics' common stockholders:




      Basic

      $          2.97


      $          3.52

      Diluted

      $          2.92


      $          3.46


      2) The following tables reconcile reported GAAP results to non-GAAP adjusted results:




      Three Months Ended March 31, 2022


      (dollars in millions, except per share data)


      Operating
      income


      Operating
      income as a
      percentage of
      net revenues


      Income tax
      expense (e)


      Equity in
      earnings of
      equity
      method
      investees, net
      of taxes


      Net income
      attributable
      to Quest
      Diagnostics


      Diluted EPS

      As reported

      $                 513


      19.7%


      $                (110)


      $                   31


      $                 355


      $                2.92

      Restructuring and
      integration charges (a)

      12


      0.4


      (3)


      —


      9


      0.07

      Gains and losses on
      investments (b)

      —


      —


      (4)


      —


      12


      0.10

      Other (c)

      2


      0.1


      (1)


      —


      1


      0.01

      Amortization expense

      27


      1.0


      (7)


      —


      20


      0.16

      ETB

      —


      —


      (5)


      —


      (5)


      (0.04)

      As adjusted

      $                 554


      21.2%


      $                (130)


      $                   31


      $                 392


      $                3.22














      Three Months Ended March 31, 2021


      (dollars in millions, except per share data)


      Operating
      income


      Operating
      income as a
      percentage of
      net revenues


      Income tax
      expense (e)


      Equity in
      earnings of
      equity
      method
      investees, net
      of taxes


      Net income
      attributable
      to Quest
      Diagnostics


      Diluted EPS

      As reported

      $                 660


      24.3%


      $                (153)


      $                   17


      $                 469


      $                3.46

      Restructuring and
      integration charges (a)

      17


      0.6


      (4)


      —


      13


      0.10

      Gains and losses on
      investments (b)

      —


      —


      (3)


      8


      5


      0.04

      COVID-19 impact (d)

      4


      0.1


      (1)


      —


      3


      0.03

      Amortization expense

      27


      1.0


      (7)


      2


      22


      0.16

      ETB

      —


      —


      (4)


      —


      (4)


      (0.03)

      As adjusted

      $                 708


      26.0%


      $                (172)


      $                   27


      $                 508


      $                3.76














       (a)

      For both the three months ended March 31, 2022 and 2021, represents costs primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business.  The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:





      Three Months Ended March 31,


      2022


      2021


      (dollars in millions)

      Cost of services

      $              3


      $              7

      Selling, general and administrative

      9


      10

      Operating income

      $            12


      $            17


      (b) 

      For the three months ended March 31, 2022, the pre-tax impact represents $16 million of net losses associated with changes in the carrying value of our strategic investments recorded in other (expense) income, net.  For the three months ended March 31, 2021, the pre-tax impact represents a non-cash impairment to the carrying value of an equity method investment, recorded in equity in earnings of equity method investees, net of taxes.





      (c)

      For the three months ended March 31, 2022, the pre-tax impact primarily represents costs associated with donations, contributions and other financial support through Quest for Health Equity, recorded in selling, general and administrative. 





      (d)

      For the three months ended March 31, 2021, represents the impact of certain items resulting from the COVID-19 pandemic including incremental costs incurred to protect the health and safety of our employees and customers, recorded in cost of services.





      (e)

      For restructuring and integration charges, gains and losses on investments, other items, amortization expense and COVID-19 impacts, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2022 and 2021.




      3)

      For the three months ended March 31, 2022, we repurchased 2.6 million shares of our common stock for $350 million.  In February 2022, our Board of Directors increased the size of our share repurchase program by $1 billion.  As of March 31, 2022, $1.3 billion remained available under our share repurchase authorization.




      4)

      The outlook for adjusted diluted EPS represents management's estimates for the full year 2022 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2022.  Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, and changes in the carrying value of our strategic investments are based on fluctuations in the investee's stock price, both of which are difficult to predict.  The following table reconciles our 2022 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS:


      Low


      High

      Diluted EPS

      $          7.88


      $          8.38

      Restructuring and integration charges (a)

      0.27


      0.27

      Amortization expense (b)

      0.68


      0.68

      Costs associated with Quest for Health Equity (c)

      0.22


      0.22

      Gains and losses on investments (d)

      0.10


      0.10

      ETB

      (0.15)


      (0.15)

      Adjusted diluted EPS

      $          9.00


      $          9.50


      (a)

      Represents estimated pre-tax charges of $45 million primarily associated with systems conversions and integration costs incurred in connection with further restructuring and integrating our business.  Income tax benefits were calculated using a combined statutory income tax rate of 25.5%.





      (b)

      Represents estimated pre-tax amortization expenses of $110 million.  Income tax benefits were calculated using a combined statutory income tax rate of 25.5%.





      (c)

      Represents estimated pre-tax charges of $35 million associated with donations, contributions and other financial support through Quest for Health Equity.  Income tax benefits were calculated using a combined statutory income tax rate of 25.5%.





      (d)

      Represents $16 million of pre-tax losses associated with changes in the carrying value of our strategic investments.  Income tax impacts were calculated using a combined statutory income tax rate of 25.5%.

      SOURCE Quest Diagnostics

      Modal title

      Also from this source

      Quest Diagnostics Declares Quarterly Cash Dividend

      Quest Diagnostics Declares Quarterly Cash Dividend

      Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors declared a...

      Quest Diagnostics to Speak at the 9th Annual Evercore Healthcare Conference

      Quest Diagnostics to Speak at the 9th Annual Evercore Healthcare Conference

      Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief ...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      Earnings Forecasts & Projections

      Earnings Forecasts & Projections

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.